e-learning
resources
Virtual 2020
Monday, 07.09.2020
Biological aspects of lung cancer
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Late Breaking Abstract - Transient Receptor Potential Vanilloid subtype 4 in patients with lung cancer
V. Bajoriunas (Kaunas, Lithuania), I. Bajoriuniene (Kaunas, Lithuania), E. Stankevicius (Kaunas, Lithuania)
Source:
Virtual Congress 2020 – Biological aspects of lung cancer
Session:
Biological aspects of lung cancer
Session type:
Oral Presentation
Number:
3938
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
V. Bajoriunas (Kaunas, Lithuania), I. Bajoriuniene (Kaunas, Lithuania), E. Stankevicius (Kaunas, Lithuania). Late Breaking Abstract - Transient Receptor Potential Vanilloid subtype 4 in patients with lung cancer. 3938
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
Late Breaking Abstract - ACE2 Overexpression Modulates Nicotine Receptors In Cell Type Specific Manner: Possible Relevance In Covid-19
Source: Virtual Congress 2021 – Late breaking basic and translational science of SARS-Cov2 and COVID-19
Year: 2021
Late Breaking Abstract - Activation of a murine skeletal muscle M3 muscarinic Designer Receptor Exclusively Activated by Designer Drug (DREADD) has cardiopulmonary consequences
Source: International Congress 2019 – Advances in COPD pharmacology
Year: 2019
Late Breaking Abstract: Expression of S100A4 in COPD
Source: Annual Congress 2010 - Novel mechanisms in COPD
Year: 2010
Late Breaking Abstract - Two Phase 3 Randomized Clinical Trials of Gefapixant, a P2X3 Receptor Antagonist, in Refractory or Unexplained Chronic Cough (COUGH-1 and COUGH-2)
Source: Virtual Congress 2020 – ALERT: Pneumothorax, cough, PAH, alveolar proteinosis
Year: 2020
Late Breaking Abstract - Role of Muscarinic M3 receptors in bronchial remodelling of severe asthma
Source: International Congress 2017 – Late-breaking findings in asthma and COPD
Year: 2017
Late Breaking Abstract - Antagonizing COVID19-induced GPR4 alleviates lung and kidney injury
Source: Virtual Congress 2021 – Late breaking basic and translational science of SARS-Cov2 and COVID-19
Year: 2021
Late Breaking Abstract - Endothelial Cell-Specific Anticoagulation Reduces Inflammation in a Mouse Model of ALI
Source: International Congress 2017 – Anti-inflammatory and pro-repair mediators in acute lung injury
Year: 2017
Association of the Monocyte Chemoattractant Protein 1 and Chemokine Receptor 2 Genetic Polymorphisms with Non-small Cell Lung Cancer in Taiwan
Source: International Congress 2017 – Clinical research in lung cancer: new valuable results on lung cancer detection, prognostic biomarkers, and tyrosine kinase inhibitors
Year: 2017
Late Breaking Abstract - Bacterial Load and Inflammation in Sputum from patients with Alpha-1-Antitrypsin Deficiency as compared with COPD Patients
Source: International Congress 2017 – Novel mechanisms and treatments for COPD
Year: 2017
Late Breaking Abstract - Treatment with ATYR1923 reduces biomarkers in COVID-19 pneumonia
Source: Virtual Congress 2021 – Diagnosis and management of COVID-19
Year: 2021
Late Breaking Abstract - Chronic Hypoxia Promotes Pulmonary Venous Smooth Muscle Cells Proliferation by Upregulating Calcium Sensing Receptor
Source: International Congress 2018 – Molecular mechanisms and treatment of pulmonary hypertension
Year: 2018
LSC - 2017 - Proteasomal Activator 200 (PA200) Regulates Cellular Proliferation: A Putative Role For IPF And Lung Cancer Pathogenesis
Source: International Congress 2017 – New insights into pathogenesis of lung disease
Year: 2017
Investigating Transient Receptor Potential V4 channel induced bronchospasm
Source: International Congress 2019 – Advances in asthma pharmacology
Year: 2019
Late Breaking Abstract - Calcium-sensing receptor activators increased in the sputum of idiopathic pulmonary fibrosis patients
Source: International Congress 2019 – Comorbidities of idiopathic pulmonary fibrosis
Year: 2019
Late Breaking Abstract: Activation of the WNT/β-catenin pathway attenuates experimental emphysema
Source: Annual Congress 2010 - Novel cellular mechanisms in lung disease
Year: 2010
Exosomes from Intermittent Hypoxia Treated Lung Adenocarcinoma Cell Line Up-regulate Programmed Death Ligand 1 Expression through HIF-1a Pathway in Macrophages
Source: Virtual Congress 2020 – Biological aspects of lung cancer
Year: 2020
Late Breaking Abstract - Role of phosphorylated Signal Transducer and Activator of Transcription 5 (pSTAT5) in non-small cell lung cancer (NSCLC)
Source: Virtual Congress 2020 – Molecular alterations and immunology in lung cancer
Year: 2020
Late Breaking Abstract - Assessment of disease progression in IPF patients using Functional Respiratory Imaging (FRI)
Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): clinical problems
Year: 2017
Late Breaking Abstract - Organoids and lung-on-chip to study SARS-CoV-2-mediated lung injury
Source: Virtual Congress 2020 – Covering COVID - the best abstracts
Year: 2020
Late Breaking Abstract - BBT-877, a Potent Autotaxin Inhibitor in Clinical Development to Treat Idiopathic Pulmonary Fibrosis
Source: International Congress 2019 – Translational aspects of idiopathic interstitial pneumonia
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept